Chewable Tablets Recalled

Reports of crushed and broken tablets have prompted Cipla USA Inc. to recall a single lot of lanthanum carbonate chewable tablets, according to the November 20, 2024, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects lanthanum carbonate chewable tablets, 1000 mg, packaged in 10-count bottles (NDC 69097-0936-98), from lot NB240316 (Exp. 12/31/25). The tablets were manufactured for Cipla USA and were distributed throughout the United States.

Cipla USA voluntarily initiated the recall on October 23, 2024. The FDA designated the recall Class II on November 12, 2024. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences. While rare, a possibility of serious harm also exists.

Lanthanum carbonate chewable tablets are a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease.